Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
Advanced Hormone Dependent Prostate Cancer
Conditions: official terms
Prostatic Neoplasms
Study Type
Observational [Patient Registry]
Study Phase
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Name: Firmagon® (degarelix)
Type: Drug
Overall Status
Prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Male
Criteria: Inclusion Criteria:

- Advanced Prostate Cancer patients to be treated with Firmagon in the context of usual clinical practice

- Written informed consent

Exclusion Criteria:

- Contraindications to Firmagon

- Patients already on Firmagon therapy
Hospital de Trauma y Emergencia Dr Federico Abete
Ingeniero Pablo Nogués, Buenos Aires, Argentina
Status: Recruiting
Start Date
March 2013
Completion Date
June 2018
Ferring Pharmaceuticals
Ferring Pharmaceuticals
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page